论文部分内容阅读
目的:探讨三联法治疗腹泻型肠易激综合征(IBS-D)的临床疗效。方法:将100例IBSD患者随机分为治疗组和对照组各50例,治疗组患者口服补脾益肠丸、培菲康和黛力新(即三联法)治疗,对照组则口服补脾益肠丸治疗。8周为一疗程,1个疗程后评价疗效。结果:治疗组显效41例,有效7例,无效2例,总有效率为96.0%;对照组显效19例,有效19例,无效12例,总有效率为76.0%。治疗组总有效率明显高于对照组,P<0.05。结论:三联法治疗IBS-D疗效可靠。
Objective: To investigate the clinical efficacy of triple therapy in treating diarrhea-predominant irritable bowel syndrome (IBS-D). Methods: One hundred cases of IBSD were randomly divided into treatment group and control group, 50 cases in each group. The patients in treatment group were treated with Bupi Yichang Wan, Peifei Kang and Deanxit Pills treatment. 8 weeks for a course of treatment, after a course of evaluation of efficacy. Results: In the treatment group, 41 cases were markedly effective, 7 cases were effective, 2 cases were ineffective, and the total effective rate was 96.0%. In the control group, 19 cases were markedly effective, 19 cases were effective and 12 cases were ineffective. The total effective rate was 76.0%. The total effective rate of the treatment group was significantly higher than that of the control group, P <0.05. Conclusion: Triple therapy is effective in treating IBS-D.